•	
Please type a plus sign (+) inside this box	+

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

C mplete if Known

Application Number 09/719,410

Filling Date December 12, 2000

First Named Inventor Burkhard Goke et al.

Group Art Unit 653

Examiner Name MOHAMED

Attorney Docket Number P03986US2

(use as many sheets as necessary)
Sheet 1 of 2

**U.S. PATENT DOCUMENTS** Pages, Columns, Lines, U.S. Patent Document Date of Publication of Name of Patentee or Applicant Cite Where Relevant Examine Cited Document MM-DD-YYYY Kind Code<sup>2</sup> Passages or Relevant Figures Appear of Cited Document Initials' No.1 Number (if known)

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Foreign Patent Doc Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T\$
m	1	W	0 98 08531 A		Eli Lilly and Company	1998-03-05	pgs. 23-24	-
								-
								-

Evaminer		Date	/ /
Examino (			~ / - / - 7
Signature	Hadol Ha Wolamed	l Considered I	(1) (19 (2) 5
Olgridiato	175000		(0)////

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a	ptus	sign (4	·) inside	this	box	$\rightarrow$	+

PTC/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subetitut	te for form 1449E	V/PT∕S		Complete if Kn wn			
				Application Number	09/719,410		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	December 12, 2000		
				First Named Inventor	Burkhard Goke et al.		
<i>-</i>				Group Art Unit			
	(use as ma	ny sheets as	necessary)	Examiner Name			
eet	2	of	2	Attorney Docket Number	P03986US2		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. RACHMAN J ET AL: "Near-normalisation of diurnal goucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM." DIABETOLOGIA, (1997 FEB) 40 (2) 205-11., XP002122529 CAVAGHAN M K ET AL: "Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance." JOURNAL OF CLINICAL INVESTIGATION, (1997 AUG 1) 100 (3) 530-7., XP002122530 the whole document BYRNE M M ET AL: "Glucagon - like peptide 1 improves the ability of the beta - cell to sense and respond to glucose in subjects with impaired glucose tolerance." DIABETES, (1998 AUG) 47 (8) 1259-65., XP002122530 the whole document

Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.